The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the approval of a new lower-dose version of an adrenaline nasal spray, EURneffy, designed for the emergency treatment of severe allergic reactions, known as anaphylaxis, in children aged four years and over. This significant development, confirmed on 12 June 2026, means that younger children in the UK will now have access to a needle-free option for managing life-threatening allergic episodes for the first time.
The newly approved 1 mg dose nasal spray is specifically indicated for children aged four years and above who weigh between 15 kg and 30 kg. This expands the availability of this type of treatment beyond the previously authorised 2 mg product, which was intended for adults and children aged 10 years and above, weighing 30 kg or more. Adrenaline is a well-established and critical treatment for serious allergic reactions, designed for immediate self-administration at the very first signs of anaphylaxis, before emergency medical services can arrive.
The nasal spray works by delivering a precise dose directly into the nostril, and crucially, it remains effective even if the nose is congested. Similar to adrenaline auto-injectors, individuals are advised to carry two doses (sprays) at all times, in case a second dose is required before an ambulance arrives. It is imperative that '999' is dialled immediately after any dose of adrenaline has been administered, regardless of the method.
This new 1 mg dose offers a vital alternative for younger patients who, until now, have relied solely on injectable adrenaline devices for emergency treatment. For many families and caregivers, the prospect of a needle-free option could alleviate some of the anxiety associated with administering emergency medication during a stressful allergic reaction.
The MHRA, responsible for regulating all medicines and medical devices in the UK to ensure their safety and effectiveness, will continue to closely monitor the safety and efficacy of this new adrenaline nasal spray, as is standard practice for any approved medicine.